Left main stem (LMS) disease is identified in up to 5 % of diagnostic angiography cases.
LMS disease (defined as >50 % stenosis angiographically). 12 The primary endpoint was the change in left ventricular ejection fraction (LVEF) at 12 months, while the secondary endpoint was a major adverse cardiac and cerebrovascular event (MACCE) at 30 days and 1 year. Surprisingly, there was a statistically significant improvment in LVEF with patients treated with PCI versus CABG (58 % versus 54 %).
PCI was also associated with a lower MACE rate at 30 days (2 % versus 13 %) with a MACE being equivalent at 1 year in the two groups. The study did have a number of limitations, including a small sample size, high use of BMS and a lower than contemporary use of left internal mammary artery (LIMA) grafts.
The Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial remains to this day the largest RCT to date to compare PCI to CABG in LMS disease. 13 The LMS subset consisted of 705 patients randomised to receiving either the first-generation TAXUS (Boston Scientific Corporation, US) DES or CABG. The primary endpoint of MACE at 1 year was comparable with 15.8 % for PCI versus 13.7 % for CABG. However, when the cohorts were further subdivided into categories based on lesion complexity, it became apparent that CABG was more favourable for the more complex lesions. The SYNTAX score was developed to objectively quantify lesion complexity and has been fully described elsewhere.
14 Stratification into tertiles of syntax score (0-22, 23-32 and >32) revealed equivalent MACCE in the lower two tertiles, but a clear superiority of CABG in the highest tertile.
The 5-year follow-up results were published in 2014. 15 The results bear a similar trend to the 1-year follow-up with similar outcomes across the whole cohort (36.9 % PCI versus 31 % CABG; P=0.12) but a statistically greater benefit of CABG in the highest risk group based on lesion complexity.
While the SYNTAX trial remains the best evidence-based RCT on revascularisation strategy, it is important to bear in mind that 45 % of patients were excluded from randomisation at the outset due to the complexity of coronary disease. Out of that group, 85 % went on to have CABG. So the evidence we have is from a pre-selected population and this has to be taken into consideration when evaluating whether PCI is an appropriate therapeutic option.
The Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main
Coronary Artery Disease (PreCOMBAT) trial was a non-inferiority trial randomising 600 patients with LMS disease to either a first-generation Cypher (Cordis Coporation, US) DES or CABG. 16 Once again the primary endpoint was MACCE at 1 year. The trial was designed to test whether PCI was non-inferior and indeed proved the non-inferiority of the percutaneous option at both 1-year and 2-years follow-up.
Boudriot et al. studied a smaller sample group of 201 patients and unlike the previous studies, PCI failed to achieve non-inferiority of MACE at 1 year. 17 Excess MACE was driven by target vessel revascularisation. Unusually for this type of comparison, stroke was not included as a clinical endpoint, which may well have contributed to the end result.
The results from the RCTs would support PCI as a reasonable alternative in the treatment of LMS disease but the studies have been hampered by limitations. These include relatively small sample sizes, different clinical endpoints among studies and the use of earlier generation DES. This has made it difficult to precisely define where PCI stands.
Meta-analysis
Athappan et al. published a meta-analysis of first-generation DES versus CABG in 2013. 18 The authors included 21 observational studies and three RCTs involving a total of 14,203 patients. The MACE rates did not differ between the PCI and CABG group up to 5 years though as has been previously noted, PCI was associated with a lower rate of stroke and higher rate of target vessel revascularisation (TVR). When the cases were stratified according to the SYNTAX score, the results were consistent with those of the main SYNTAX trial with comparable results for the lower two tertiles but a clear superiority of CABG for the highest group.
Influence of Stent Type/Lesion Location and Intravascular Imaging

Stent Type
If PCI is to be undertaken in LMS disease, it is crucial to minimise ISR and thrombosis. A meta-analysis by Pandya et al. comprising 44 studies, showed that DES were associated with a better outcome than BMS. 19 The Intracoronary outcomes with both types of stents. 20 The ISAR-LEFT MAIN 2 study compared second-generation zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) and once again showed similar clinical and angiographic outcomes at 1 year. 21 Thus, the types of DES from a similar generation do not seem to influence outcome.
Lesion Location
In an analysis of the Drug-Eluting Stent For Left Main Coronary Artery Disease (DELTA) registry comparing ostial/mid-shaft lesion versus distal lesions, Naganuma et al. demonstrated a higher rate of TLR with distal lesions. 22 This primarily drove the higher MACE rates and while there was a trend towards higher mortality and MI, this was not sustained after propensity score matched analysis.
Distal bifurcation lesions present a particularly challenging anatomy to treat. Notwithstanding the increased complexity of such lesions, no technique has been standardised as the technique of choice in LMS bifurcation treatment. In an analysis of the cohort from the ISAR-LEFT MAIN study, the need for multiple stents was an independent predictor of adverse MACE. 23 There seemed to be a better outcome with the use of the Culotte technique as opposed to the T-stent technique with an ISR rate of 21 % and 56 % and a TLR rate of 15 % and 56 %, respectively.
Intravascular Ultrasound
The potential catastrophic consequences of stent thrombosis or has not yet been clinically validated. 26 In an analysis of four Spanish registries, De la Torre et al. found better 3-year outcomes with IVUS-guided revascularisation with a statistically significant reduction in mortality, TLR and MI (88.7 % versus 83.6 %). 27 This was even more relevant in a subgroup analysis of patients with distal LMS lesions with better survival rates despite the lower number of patients in that subset.
Guidelines
While the results of the two major RCTs are still awaited, the European and American societies have both issued guidelines on revascularisation of patient with LMS disease (see Tables 1 and 2 ). 
On-going Trials
Traditionally, patients with LMS disease as well as additional severe coronary disease elsewhere tend to be referred for CABG assuming decent distal targets are available for grafting. The class 1 recommendation of CABG in high Syntax scores is unlikely to be challenged in RCTs. However, the role in less-severe disease needs to be firmly established. In that respect, we look forward to the results of two trials that hopefully will settle the matter. The primary endpoint is MACE at 2 years.
While the overarching aim of the two trials is to compare PCI with CABG in less 'complex' anatomy, it is worth pointing out the subtle differences in inclusion criteria between the two trials. In the NOBLE trial, a significant LMS lesion is defined as having either a visually estimated diameter stenosis >50 % or FFR <0.8. In the EXCEL trial, it is defined as having either a visually estimated diameter of >70 % or 50-70 % with a FFR <0.8 or MLA <6 mm 2 . Results from both trials are expected in 2016. 
Conclusions
While the treatment of LMS disease has historically lain in the realm of the surgery, rapid advancements in the field of percutaneous coronary intervention has provided another viable therapeutic option. Both the American and European societal guidelines have endorsed PCI in patients with less-complex coronary disease while CABG still maintains a class I recommendation across all groups. The data to firmly establish the role of percutaneous treatment are currently lacking and the two on-going EXCEL and NOBLE trials will hopefully take us a step further in clarifying the role of PCI in the treatment of LMS disease. n
